ALLODYNIC THERAPEUTICS, LLC
NORTH MIAMI, FLORIDA

Allodynic Therapeutics, LLC is a private clinical-stage biopharmaceutical company dedicated to advancing the treatment of various neuropathic pain conditions. Founded in 2010 by Dr. Annette Toledano, who is both a physician and drug developer, Allodynic aims to revolutionize pain management with its innovative approach centered around ALLOD-2, their lead product candidate. ALLOD-2 is being investigated for conditions such as episodic migraine treatment and prevention, chronic low back pain, trigeminal neuralgia, postherpetic neuralgia, fibromyalgia, vulvodynia, diabetic peripheral neuropathy, among others. It works by blocking processes that contribute to pain generation, specifically targeting neuroinflammation via the immune system and pro-inflammatory cytokines. The company's initial product, ATNC05, a combination of a Toll-Like Receptor-4 (TLR4) antagonist and an alpha-2 adrenergic agonist, has shown promise in clinical trials for chronic back pain and was granted FDA breakthrough designation for this indication. Following further development, ALLOD-2 emerged as a dual-action product that also inhibits COX-2 alongside blocking pro-inflammatory cytokines. Allodynic Therapeutics is headquartered in North Miami, Florida, and maintains two active Investigational New Drug applications (INDs) targeting migraine and chronic low back pain. The company is actively conducting phase 2B clinical trials to address acute treatment of migraines with associated nausea and plans for additional FDA breakthrough designations based on these studies' outcomes. With prospects poised in the pharmaceutical landscape, Allodynic collaborates closely with partners eager to advance its pipeline, promising significant contributions to unmet medical needs in pain management. For more details, visit their website at allodynictherapeutics.com.